Toward future therapies in progressive supranuclear palsy.
There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.
Burn
David J
DJ
Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk
Warren
Naomi M
NM
D018663:Adrenergic Agents / Q000627:therapeutic use; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D006801:Humans; D018377:Neurotransmitter Agents / Q000627:therapeutic use; D010166:Palliative Care; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy / Q000628:therapy*
D018663:Adrenergic Agents; D018726:Anti-Dyskinesia Agents; D018678:Cholinergic Agents; D015259:Dopamine Agents; D018377:Neurotransmitter Agents